u/Ok_Refrigerator3780

The author argues Rocket Pharmaceuticals' Danon program has materially improved after the revised Phase 2 protocol, with the first three patients completing safety observation without TMA, capillary leak syndrome or other major safety concerns. They see the regulatory path as constructive because FDA has not indicated a fundamental pivotal redesign and has encouraged development in female Danon patients, while KRESLADI approval and the $180M Priority Review Voucher sale extend cash runway into Q2 2028. The stated catalyst is the next regulatory and clinical updates expected in H2 2026, with RP-A501 viewed as increasingly interesting as the story develops. The main stated risk is that the program is not fully de-risked and more patients are still needed to confirm the safety improvement.